BACKGROUND/AIM: The study aims to describe the role of diabetes in patients with heart failure. METHODS: In all, 1052 chronic heart failure patients were included in the FARmacology and NeuroHumoral Activation (FAR NHL) multicenter prospective registry. They had ejection fraction below 50% and were on stable medication for at least 1 month. RESULTS: More than one-third (38.9%) of the patients had diabetes mellitus (DM). Diabetic patients (N = 409) were older (median 67 vs. 64, p < 0.001), had higher body mass index (BMI) (30 vs. 28 kg/m2, p < 0.001), much more frequently had ischemic heart disease (71 vs. 47%, p < 0.001), hypertension (80 vs. 67%, p < 0.001), dyslipidemia (89 vs. 69%, p < 0.001), worse renal function (estimated glomerular filtration rate [eGFR] median 63 vs. 73 mL/min/1.73 m2, p < 0.001), and higher N-terminal pro-brain natriuretic peptide (NT-proBNP) (median 681 vs. 463 pg/mL, p = 0.003). All-cause death, left ventricle assist device implantation, and orthotopic heart transplantation were set as the combined primary end point, which was present in 15.5% (163 patients) within the 2-year follow-up. In the 2-year follow-up, 81.0% of patients with diabetes survived without a primary end point, while 85.4% of the patients without diabetes survived, the difference being on the verge of statistical significance (p = 0.089). DM is a statistically significant predictor of NT-proBNP value in univariate analysis, but it is not an independent predictor in a multivariate analysis. When the NT-proBNP level was high, the presence of DM did not influence the prognosis. CONCLUSION: The combination of diabetes and NT-proBNP levels may better stratify the prognosis of patients with chronic heart failure.

1st Department of Internal Medicine Cardioangiology St Anne's University Hospital Faculty of Medicine Masaryk University Brno Czech Republic

Department of Cardiology 2nd Medical Faculty Charles University and University Hospital Motol Prague Czech Republic

Department of Cardiology Na Homolce Hospital Prague Czech Republic

Department of Internal Cardiology Medicine University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Geriatrics and Practical Medicine University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic

See more in PubMed

Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;241(19):2035‐2038. doi:10.1001/jama.1979.03290450033020 PubMed DOI

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599‐3726. doi:10.1093/eurheartj/ehab368 PubMed DOI

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre‐diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255‐323. doi:10.1093/eurheartj/ehz486 PubMed DOI

Dauriz M, Targher G, Laroche C, et al. Association between diabetes and 1‐year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC‐HFA Heart Failure Long‐Term Registry. Diabetes Care. 2017;40(5):671‐678. doi:10.2337/dc16-2016 PubMed DOI

Demant MN, Gislason GH, Kober L, Vaag A, Torp‐Pedersen C, Andersson C. Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study. Diabetologia. 2014;57(8):1595‐1600. doi:10.1007/s00125-014-3259-z PubMed DOI

Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country‐years and 2.7 million participants. Lancet. 2011;378(9785):31‐40. doi:10.1016/S0140-6736(11)60679-X PubMed DOI

Bhalla MA, Chiang A, Epshteyn VA, et al. Prognostic role of B‐type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004;44(5):1047‐1052. doi:10.1016/j.jacc.2004.05.071 PubMed DOI

Peng Q, Hu W, Su H, Yang Q, Cheng X. Levels of B‐type natriuretic peptide in chronic heart failure patients with and without diabetes mellitus. Exp Ther Med. 2013;5(1):229. doi:10.3892/etm.2012.760 PubMed DOI PMC

Fringu FI, Sitar‐Taut AV, Caloian B, et al. The role of NT pro‐BNP in the evaluation of diabetic patients with heart failure. Acta Endocrinol (Buchar). 2020;16(2):183‐191. doi:10.4183/aeb.2020.183 PubMed DOI PMC

Lábr K, Špinar J, Pařenica J, et al. Renal functions and prognosis stratification in chronic heart failure patients and the importance of neutrophil gelatinase‐associated lipocalin. Kidney Blood Press Res. 2018;43(6):1865‐1877. doi:10.1159/000495819 PubMed DOI

Špinarová L, Špinarová M, Goldbergova‐Pavkova M. Prognostic impact of copeptin and mid‐regional pro‐adrenomedullin in chronic heart failure with regard to comorbidities. J Cardiovasc Dis Diagn. 2018;6:326. doi:10.4172/2329-9517.1000326 DOI

Spinar J, Spinarova L, Malek F, et al. Prognostic value of NT‐proBNP added to clinical parameters to predict two‐year prognosis of chronic heart failure patients with mid‐range and reduced ejection fraction ‐ a report from FAR NHL prospective registry. PLoS One. 2019;14(3):e0214363. doi:10.1371/journal.pone.0214363 PubMed DOI PMC

Špinarová L, Špinar J, Pařenica J, et al. The FAR NHL register and humoral activation. Kardiologicka Rev. 2020;22(2):51‐57.

Špinarová M, Špinar J, Špinarová L, et al. Relation between mid‐regional pro‐adrenomedullin in patients with chronic heart failure and the dose of diuretics in 2‐year follow‐up—Data from FAR NHL registry. Medicina (Mex). 2022;58(10):1477. doi:10.3390/medicina58101477 PubMed DOI PMC

Lábr K, Špinar J, Pařenica J, et al. Beta‐blockers in chronic heart failure as recorded in the FAR NHL registry. Kardiologicka Rev. 2017;19(1):68‐72.

Špinarová M, Špinar J, Pařenica J, et al. Prescription and dosage of raas inhibitors in patients with chronic heart failure in the FAR NHL registry. Vnitr Lek. 2019;65(1):13‐18. PubMed

Špinarová M, Špinar J, Pařenica J, et al. Prescription and dosing of diuretics in patients with chronic heart failure in the FAR NHL register. Kardiologicka Rev. 2020;22(2):58‐62.

Taborsky M, Aiglova R, Lazarova M, et al. Beta‐blockers utilization in heart failure patients: sub‐analysis of a nation‐wide population‐based study in The Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021;15:402‐407. doi:10.5507/bp.2020.057 PubMed DOI

Aiglova R, Taborsky M, Lazarova M, et al. Angiotensin‐converting enzyme inhibitors, angiotensin‐II‐receptor antagonists and angiotensin‐receptor blocker/neprilysin inhibitor utilization in heart failure patients: sub‐analysis of a nation‐wide population‐based study in The Czech Republic. Biomed Pap‐Olomouc. 2022;166:322‐327. doi:10.5507/bp.2021.035 PubMed DOI

Marx N, Federici M, Schütt K, et al. ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:4043‐4140. doi:10.1093/eurheartj/ehad192 PubMed DOI

Táborský M, Skála T, Lazárová M, et al. Trends in the treatment and survival of heart failure patients: a nationwide population‐based study in The Czech Republic. Esc Heart Fail. 2021;8(5):3800‐3808. doi:10.1002/ehf2.13559 PubMed DOI PMC

Dauriz M, Mantovani A, Bonapace S, et al. Prognostic impact of diabetes on long‐term survival outcomes in patients with heart failure: a meta‐analysis. Diabetes Care. 2017;40(11):1597‐1605. doi:10.2337/dc17-0697 PubMed DOI

Agostoni P, Paolillo S, Mapelli M, et al. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long‐term comparison. Eur J Heart Fail. 2018;20(4):700‐710. doi:10.1002/ejhf.989 PubMed DOI

Andreasová T, Vránová J, Vondráková D, et al. Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure. J Int Med Res. 2020;48(8):30006052094786. doi:10.1177/0300060520947869 PubMed DOI PMC

Paolillo S, Salvioni E, Perrone Filardi P, et al. Long‐term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction insights from the MECKI score database. Int J Cardiol. 2020;317:103‐110. doi:10.1016/j.ijcard.2020.04.079 PubMed DOI

Spinar J, Jarkovsky J, Spinarova L, et al. AHEAD score—long‐term risk classification in acute heart failure. Int J Cardiol. 2016;202:21‐26. doi:10.1016/j.ijcard.2015.08.187 PubMed DOI